Objective: This study assessed the longitudinal changes in renal volume after renal artery stenting (RAS) to determine if renal mass is preserved by stenting. Methods: The study cohort consisted of 38 patients with longitudinal imaging available for renal volume quantification before and after RAS. Renal volume was estimated as (kidney length) ؋ (width) ؋ (depth/2) based on preoperative renal imaging. For each patient, the clinical response of blood pressure (BP) and renal function to RAS was categorized according to modified American Heart Association guidelines. Changes in renal volume were assessed using paired nonparametric analyses. Results: The cohort was a median age of 69 years (interquartile range [IQR], 60-74 years). A favorable BP response was observed in 11 of 38 patients (28.9%). At a median interval between imaging studies of 21 months (IQR, 13-32 months), ipsilateral renal volume was significantly increased from baseline (146.8 vs 133.8 cm 3 ;P ‫؍‬ .02). This represents a 6.9% relative increase in ipsilateral kidney volume from baseline. A significant negative correlation between preoperative renal volume and the relative change in renal volume postoperatively (r ‫؍‬ ؊0.42; P ‫؍‬ .0055) suggests that smaller kidneys experienced the greatest gains in renal volume after stenting. It is noteworthy that the 25 patients with no change in BP or renal function-clinical failures using traditional definitions-experienced a 12% relative increase in ipsilateral renal volume after RAS. Multivariate analysis determined that stable or improved renal volume after stenting was an independent predictor of stable or improved long-term renal function (odds ratio, 0.008; 95% confidence interval, 0.000-0.206; P ‫؍‬ .004). Conclusions: These data lend credence to the belief that RAS preserves renal mass in some patients. This benefit of RAS even extends to those patients who would be considered treatment failures by traditional definitions. Patients with stable or increased renal volume after RAS had more stable renal function during long-term follow-up, whereas patients with renal volume loss after stenting were prone to deterioration of renal function. ( J Vasc Surg 2012;55:774-80.)
The treatment of renal artery (RA) occlusive disease (RAOD) with RA stenting (RAS) is typically aimed at improving blood pressure (BP) control or salvaging renal function. Recent studies have documented BP or renal function improvement in 34% to 80% of patients after RAS, while others derive no clear benefit. [1] [2] [3] [4] [5] [6] [7] A key determinant of the response to RAS may be the condition of the kidney downstream of an RA stenosis. Chronic renal ischemia due to RAOD may induce nephrosclerosis, leading to renal cortical thinning, parenchymal atrophy, and progressive loss of kidney mass. The clinical consequence of unabated nephrosclerosis is progressive hypertension or renal insufficiency that is poorly responsive to renal revascularization.
The extent to which renal parenchymal changes induced by RAOD may be reversed by RAS is poorly understood. Some proponents of RAS contend that stenting will prevent further ischemic injury to the kidney and preserve renal mass, even if there is no improvement in BP or renal function. Currently there are limited data to support that notion. The purpose of this study was to assess the longitudinal changes in renal volume after RAS to determine whether stenting preserves renal mass.
METHODS
This study was approved by the Institutional Review Boards of the University of Texas Southwestern Medical School and the Dallas Veterans Affairs Medical Center.
Study cohort. This retrospective study examined the outcomes for a cohort of 38 patients who underwent primary RAS at the University of Texas Southwestern Medical School and its affiliated hospitals between January 2000 and July 2008. The principal inclusion criterion was the availability of longitudinal renal imaging with contrastenhanced computed tomography (CT) or magnetic resonance (MR) scans for quantification of renal volume before and after RAS. Exclusion criteria included nonatherosclerotic RA lesions, secondary RA lesions due to restenosis after previous angioplasty or stenting, inadequate clinical follow-up to assess the clinical outcome of RAS, or a lack of longitudinal imaging sufficient to quantify renal volume. The primary indication for RAS was treatment of hyperten-sion in 21 of the 38 patients (55.3%) and renal insufficiency in 17 (44.7%).
Clinical data collection. Demographic, clinical, anatomic, and procedural data pertinent to RAS were collected for each patient. BP control was assessed by calculating an average resting BP (measured while seated) and the average number of antihypertensive medications from two to three clinic visits before stenting and at the last follow-up after stenting, as described previously. 6 All medications with a potential for influencing BP were included in the tally of antihypertensive medications, including diuretics and nitrates, even if those medications were prescribed for cardiac indications.
Renal function was characterized by serum creatinine (mg/dL), estimated glomerular filtration rate (eGFR), and the proportion of patients requiring renal replacement therapy. Average preoperative and postoperative serum creatinine and eGFR were calculated from two to three clinic visits. The abbreviated Modification of Diet in Renal Disease formula was used to calculate eGFR: 186 ϫ (serum creatinine)Ϫ1.154 ϫ (age)Ϫ0.203 ϫ (0.742 if female) ϫ (1.210 if African American). 8 Patients requiring renal replacement therapy were designated as having an eGFR of 10 mL/min/1.73 m 2 .
Definition of clinical response to RAS. Patients were categorized as BP and renal function "responders" or "nonresponders" by a modification of American Heart Association reporting guidelines, 9 as reported previously. 6, 7 The BP response to RAS was assessed by comparing the average poststenting BP and number of antihypertensive medications at last follow-up with the average prestenting BP and number of antihypertensive medications for each patient. "BP responders" were defined by an average postoperative BP of Ͻ160/90 mm Hg on a reduced number of antihypertensive medications or a reduction in average diastolic BP to Ͻ90 mm Hg on the same number of medications after RAS. All other patients were categorized as "BP nonresponders."
The renal function response to RAS was defined in accordance with American Heart Association guidelines, 9 which have been used in prior studies. 1, 2, 5, 7 "Renal function responders" were defined by an improvement in the average poststenting eGFR at the last follow-up of Ն20%, compared with the average prestenting eGFR. Patients with stable renal function (Ͻ20% change in eGFR) or worsened renal function (Ն20% decrease in eGFR) after RAS were analyzed in aggregate as "renal function nonresponders."
Renal volume determination. Contrast-enhanced CT or MR scans were used to measure kidney pole-to-pole length, medial-to-lateral width, and anterior-to-posterior depth. All measurements were performed in duplicate by an unblinded reader (J.G.M.) and averaged. From these average measurements, the estimated kidney volume was calculated: (kidney length) ϫ (width) ϫ (depth/2). This technique for assessing kidney volume was previously validated in an autopsy study 10 and used in prior studies. 6, 11 Increased kidney volume was defined as an increase of Ն5% over baseline, whereas decreased kidney volume required a decline in kidney volume by Ն5%. Stable kidney volume was defined by any change in kidney volume of Ͻ5% over baseline. When correlating longitudinal changes in kidney volume with changes in eGFR over time, the two kidney volumes were averaged for patients with bilateral stenting to yield a net change in kidney volume.
Statistical analysis. The primary end point of the study was kidney volume after stenting. Secondary end points included procedural complications, BP renal function response to stenting, and survival. Categoric data were reported as proportions and compared using 2 , Fisher exact, or Cochran-Armitage trend tests. Continuous data were reported as medians with interquartile ranges (IQRs) and compared between groups with Mann-Whitney U, Wilcoxon matched pairs, and Kruskal-Wallis tests, as appropriate. Stepwise multivariate logistic regression analysis was performed to identify independent predictors of stable (or improved) long-term renal function after RAS. Variables that were significant (P Ͻ .05) on univariate analysis were incorporated into the regression model. Survival was calculated according to the Kaplan-Meier technique. Survival curves were compared using the log-rank test. The threshold for significance was .05. Statistical analysis was performed using SAS 9.13 software (SAS Institute Inc, Cary, NC).
RESULTS
Cohort characteristics before stenting. The baseline demographics and comorbid conditions for the cohort are reported in Table I . The age and comorbidities shared by the cohort typify a patient population with RAOD. Before stenting, the median systolic BP was 154 mm Hg (IQR, 136-171 mm Hg) and median diastolic BP was 76 mm Hg (IQR, 66-90 mm Hg). Patients were taking a median of three preoperative antihypertensive medications (IQR, 3-4 medications). The median preoperative serum creatinine was 1.45 mg/dL (IQR, 1.00-1.73 mg/dL). In 17 of 38 patients (44.7%), baseline serum creatinine was Ն1.5 mg/ dL. No patients required renal replacement therapy before RAS. The median eGFR before stenting for the cohort was 51 mL/min/1.73 m 2 (IQR, 42-60 mL/min/1.73 m 2 ).
Procedural details. Forty-five RAs were treated in 38 patients, representing 7 bilateral (18.4%) and 31 unilateral (71.6%) stenting procedures. Only 2 of the 45 stented RAs involved solitary kidneys. The median degree of stenosis of the stented RAs was 75% (IQR, 70%-80%). All stents used to treat these stenoses were balloon-expandable stents with a median stent diameter of 6 mm (IQR, 5-6 mm) and length of 18 mm (IQR, 15-18 mm). Predilatation was used before stenting in 3 of 38 patients (7.9%). Embolic protection was used in one patient (2.6%).
No immediate complications were noted. Two late restenoses were documented on follow-up surveillance at 7 and 25 months after stenting. In both cases, the early and late BP and renal function responses to RAS were congruent, suggesting that the restenosis had no effect on the clinical outcome for stenting in these patients.
Cohort outcomes. For the cohort at large, the median duration of follow-up at which both clinical data and imaging were available was 21 months (IQR, 13-32 months). To assess renal function at later times, eGFR was assessed at a median of 63 months after stenting (IQR, 33-98 months) in the absence of concurrent imaging. The outcomes for the cohort are summarized in Table II . RAS significantly improved systolic and diastolic BP, but stenting did not decrease the number of antihypertensive medications required for BP control. Renal function was not significantly altered by RAS, based on a comparison of serum creatinine, eGFR, and proportion of patients who required hemodialysis before and after stenting.
Patient-specific clinical outcomes. Of the 38 patients, 11 (28.9%) were categorized as BP responders by the definition outlined in the Methods section. Responders experienced a much greater improvement in systolic BP than nonresponders (Ϫ32 [IQR, Ϫ64 to 14] vs Ϫ8 [IQR, -35 to 9] mm Hg), although this difference was not statistically significant (P ϭ .14). Diastolic BP was also improved to a greater extent in responders than in nonresponders (-19 [IQR, -31 to Ϫ1] vs 0 [IQR, -14 to 8] mm Hg; P ϭ .03). In addition to lower systolic and diastolic BPs, significantly fewer antihypertensive medications were required for responders compared with nonresponders (-1 [IQR, -2 to 0] medication vs no change [IQR, 0-1] in medication; P Ͻ .0001).
Three patients (7.9%) were renal function responders based on an improvement in eGFR poststenting of Ն20% over baseline. The median change in eGFR among these three patients was 54 mL/min/1.73 m 2 (IQR, 28-119 mL/min/1.73 m 2 ), whereas the median change in eGFR among renal function nonresponders was nil (IQR, -23 to 0 mL/min/1.73 m 2 ).
Kidney morphometrics and renal volume. Baseline and poststenting measurements of kidney pole-to-pole length, anterior-to-posterior depth, medial-to-lateral width, and calculated renal volume are provided in Table III . At a median interval between the before and after stenting imaging studies of 21 months (IQR, 13-32 months), ipsilateral kidney width, depth, and volume were significantly increased from baseline. For the cohort as a whole, ipsilateral renal volume increased by 6.9% from baseline (IQR, Ϫ7.2% to 29.9% change). By comparison, the contralateral, unstented kidneys of patients undergoing unilateral stenting had a median renal volume loss of 52.7% (IQR, -61.0% to -46.7% change). It is noteworthy that the 25 patients who were deemed "nonresponders" to RAS by their postoperative BP and renal function-clinical failures using traditional definitions-experienced a 12% relative increase in ipsilateral renal volume after RAS.
A significant negative correlation was observed between preoperative renal volume and the relative change in stented kidney volume postoperatively (r ϭ Ϫ0.42; P ϭ .0055), indicating that smaller kidneys experienced the greatest gains in renal volume after stenting. It should be noted, though, that the median preoperative kidney poleto-pole length was 10.0 cm (IQR, 9.1-10.7 cm), and only 25% of kidneys in the cohort had a pole-to-pole length of Ͻ9.1 cm (Table III) . Net changes in stented kidney volume were used to categorize patients as having stable, decreased, or increased stented kidney volumes, according to the definitions provided in the Methods section. Stable kidney volumes were documented in 23.7%, increased kidney volumes in 50.0%, and the remaining 26.3% had a net decrease in kidney volume of Ն5%, compared with baseline.
An important question is whether the changes in renal mass induced by RAS translate into improved clinical outcomes over the long-term. First, the relationship between postoperative changes in kidney volume changes and late survival was examined. Survival was not significantly different between patients with decreased kidney volume vs those who had stable or increased renal volume (log-rank test, P ϭ .63; Fig 1) . The relationship between longitudinal changes in kidney volume and changes in renal function during late follow-up was also examined. For this analysis, clinical follow-up at a median of 63 months after stenting (IQR, 33-98 months) was used. The relative change in postoperative renal volume from before to after stenting correlated significantly with longitudinal changes in eGFR at late clinical follow-up (r ϭ 0.47; P ϭ .003). This relationship is depicted in Fig 2. Patients with kidney volume loss after stenting (Fig 2, A) had a significant decrease in eGFR during the 71 months after stenting (P ϭ .02), whereas patients with stable or increased kidney volume (Fig 2, B and C) had no significant change in eGFR at 53 and 86 months of follow-up (P ϭ .63 and P ϭ .38), respectively. The relative change in eGFR from baseline was significantly different among the three groups (P Ͻ .004) and paralleled the changes in kidney volume.
A comparison of patients with stable or improved renal function vs those who experienced deterioration in late renal function (Ն20% decline in eGFR from prestenting) identified four variables that differed significantly between the two groups (Table IV) . Three of the four variables were included in a multivariate model to identify predictors of stable or improved renal function at late follow-up. Preoperative serum creatinine was not included in the model because preoperative eGFR was included. Multivariate analysis identified two independent predictors of stable or The number at risk is provided for each interval. The standard error for the stable/improved renal volume and decreased renal volume groups was Ͼ10% at 80 and 22 months, respectively. The difference in survival between the two groups was not significant (log-rank test, P ϭ .63). improved long-term renal function: (1) age (odds ratio, 1.3; 95% confidence interval, 1.0-1.5; P ϭ .016); and (2) stable or improved kidney volume after RAS (odds ratio, 0.008; 95% confidence interval, 0.000-0.206; P ϭ .004). These data indicate that patients with stable or improved kidney volume after RAS have a Ͻ1% chance of experiencing a late deterioration in eGFR of Ͼ20% from baseline.
To help clinicians select patients for RAS, we compared the cohort with stable or increased kidney volume after stenting with the cohort with decreased kidney volume to identify preoperative clinical or morphologic differences in the groups. There were no significant differences between the two cohorts in age, systolic or diastolic BP, number of antihypertensive medications, clonidine use, eGFR, incidence of bilateral RA stenosis or solitary kidneys, kidney length, kidney width, or kidney depth.
DISCUSSION
The traditional indications for RAS in patients with RAOD are control of renal function and salvage of renal function. Although proponents of stenting have suggested that stenting may preserve renal mass, there are limited data to support that contention. The current study provided evidence to support this concept: a net increase in kidney volume of 6.9% was seen after RAS. Indeed, half of the patients experienced a net increase in kidney volume of at Ն5% over baseline, and one-quarter had stable kidney volumes (Ͻ5% change from baseline) after stenting. By comparison, the contralateral, unstented kidneys of patients undergoing unilateral RAS had significant ongoing loss of kidney volume during follow-up. This finding provides additional circumstantial evidence to suggest that RAS preserves renal mass. Interestingly, the positive effect on kidney volume was not necessarily concentrated in those patients who experienced a favorable BP or renal function response to stenting. In fact, there was a 12% net increase in kidney volume in the subset of patients who would have been considered treatment failures by traditional definitions.
It may be argued that preserving kidney mass is only beneficial if it is associated with improved clinical outcomes, such as improved long-term renal function. In the current study, we confirmed an association between changes in postoperative kidney volume and late renal function. Specifically, patients with stable or increased kidney volume had stable long-term renal function in Ͼ89% of cases, whereas the subset with decreased kidney volume after RAS commonly experienced progressive deterioration in renal function. These data suggest that longitudinal changes in kidney volume induced by RAS will have a significant bearing on future renal function.
The results of the current study appear to lend credence to the purported potential of RAS to preserve renal mass. These data raise an important question regarding the end points that should be used to judge the success or failure of RAS. In addition to early changes in BP and renal function, our data suggest that changes in kidney volume after RAS may be a surrogate marker for late changes in renal function. As such, these data provide a rationale for using changes in kidney volume after stenting as an additional early end point to assess outcomes for RAS. Many interventionalists use pole-to-pole kidney length to assess kidney size in patient selection for RAS, but the data in Table III show that kidney length was less sensitive than kidney width, depth, or volume in detecting changes in kidney size after RAS. These data question the utility of using kidney length in patient selection and argue instead for using kidney volume in assessing parenchymal mass before and after stenting. To our knowledge, the current study is one of only two reports to focus primarily on kidney volume changes after RAS. Davies et al 11 reported a series of 592 RA interventions in which one-third had a loss of renal volume after stenting. Those patients with loss of parenchymal volume had a higher rate of progression to dialysis and worse survival. The results of the current study confirm and extend the results from the Davies study. In the current study, patients with stable or increased renal volume were the primary focus, rather than those with decreased kidney volume after stenting. We found that stabilization or increase in renal mass after stenting was an independent predictor of stable or improved renal function at late follow-up.
The results of the current study are provocative, but some limitations must be acknowledged. The most obvious limitation is the small sample size. Unfortunately, the clinical vascular laboratories at our affiliated hospitals did not report kidney size in all three dimensions during the study period, which excluded many RAS patients from this study. Additional validation of the findings of this study in a larger cohort is warranted before these data can be incorporated into clinical practice.
A second limitation is the applicability of kidney volumes derived from CT angiography and MR angiography when most patients do not undergo either assessment before RAS. Future studies should be aimed at validating these findings using duplex ultrasound imaging to measure kidney volume. We recommend that clinical vascular laboratories routinely measure kidney size in all three dimensions so that renal volume can be monitored longitudinally.
Finally, duplex-derived renal resistive indices were not available for most patients, 12 so we were unable to determine the relative utility of renal volumes compared with resistive indices as predictors of long-term changes in renal function. Despite these relative limitations, the results of the current study merit further investigation. Although it is tempting to view the potential of RAS to stabilize or increase renal volume as an additional justification for RAS, further validation of these data is essential before clinical practice patterns may be altered.
CONCLUSIONS
The data in this study lend credence to the belief that RAS preserves renal mass in some patients. This benefit of RAS even extends to those patients who would be considered treatment failures by traditional definitions. Patients with stable or increased renal volume after RAS had more stable renal function during long-term follow-up, whereas patients with renal volume loss after stenting were prone to deterioration of renal function. 
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